Search

everythinglearnresearchcommunity

for

Search:↓

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Certain cancer drugs can cause skin issues like rashes and itching.

A woman with lupus developed rare skin growths that went away on their own.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Glioma treatment may improve with new therapies and technologies.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

Baricitinib is effective as a treatment for severe hair loss.

Early detection and complete surgical removal are crucial for better outcomes in treating pilomatrix carcinoma.

Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

Etanercept effectively treated a severe skin condition when other treatments failed.

Tph cells are linked to the severity of systemic lupus erythematosus.